Abstracts - faqs.org

Abstracts

Health care industry

Search abstracts:
Abstracts » Health care industry

First launch for Exanta-in Germany

Article Abstract:

The introduction of AstraZeneca's Exanta (ximelagatran) in Germany that is used to arrest venous thromboembolic (VTE) events in elective hip or knee replacement operation and the procedures associated in application have been described. The hurdles faced by AstraZeneca's Exanta (ximelagatran) in getting approval from United Kingdom (UK) and Ireland despite European Union's mutual recognition procedure have been discussed.

Publisher: Standard & Poor's Corporation
Publication Name: Standard & Poor's Industry Surveys: Health Care
Subject: Health care industry
ISSN: 0196-4666
Year: 2004
United Kingdom, Germany, Facilities & equipment, Product introduction, New Products/Services, Equipment and supplies, AstraZeneca PLC, AZN, Orthopedic surgery, AstraZeneca Exanta (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


WHO removes two Cipla HIV drugs from its list

Article Abstract:

World Health Organization's removal of Cipla's antiretrovirals, lamivudine 150 mg (10 tablets) and lamivudine 150mg plus zidovudine 300mg (10 tablets), drugs that are used for treating HIV from its prequalification list for not following good clinical practice (GCP), good laboratory practice (GLP) etc., has evoked response from the company and other nongovernmental organization as furnished.

Publisher: Standard & Poor's Corporation
Publication Name: Standard & Poor's Industry Surveys: Health Care
Subject: Health care industry
ISSN: 0196-4666
Year: 2004
India, Antiviral agents, World Health Organization, Anti-HIV agents, Cipla Ltd.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


US Senator hits out at FDA for muzzling SSRI reviewer

Article Abstract:

Republic Senator Charles Grassley of Iowa has criticised the United States Food and Drug Administration for not preventing the physicians from prescribing the Selective Serotonin Reuptake Inhibitor (SSRI) drugs to treat children suffering from depression despite opposition from Office of Drug Safety. Information on the SSRI drug has been furnished.

Publisher: Standard & Poor's Corporation
Publication Name: Standard & Poor's Industry Surveys: Health Care
Subject: Health care industry
ISSN: 0196-4666
Year: 2004
Pharmaceutical Preparation Manufacturing, Services information, Iowa, Antidepressant Preparations, Children, Services, Drug therapy, Control, Prescriptions (Drugs), Antidepressants, Legislators, Serotonin uptake inhibitors, Selective serotonin reuptake inhibitors, United States. Food and Drug Administration, Senators, Grassley, Charles E.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Pharmaceutical industry, Standards, Licensing, certification and accreditation
Similar abstracts:
  • Abstracts: The demand for Medicare supplemental insurance benefits: the role of attitudes toward medical care and risk. Changes in the use of diagnostic technologies among Medicare patients, 1985 and 1990
  • Abstracts: A virtual playground for sick kids. Welcome to Appalachia online. Connect the docs
  • Abstracts: Consent and informed consent in perinatal and neonatal settings. Perinatal group B streptococcal infections: the nurse's role in identification and prophylaxis
  • Abstracts: What will reform mean to the invisible poor? Back to schools: Phoenix health system finds poor families more trusting of school-based centers
  • Abstracts: Supplier-managed inventory: schedule sharing. Six ways to reduce inventory. Inventory management for cardiac catheterization labs: the Princeton-Baptist Medical Center experience
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.